UroGen Pharma (URGN) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
UroGen Pharma (URGN) has outperformed Viridian Therapeutics (VRDN) over the past year, gaining 124.3% versus a loss of 14.4%. Over five years, URGN leads with a +116.4% price change compared with +9.3% for VRDN. Viridian Therapeutics is the larger company by market cap ($2.11 billion vs $1.80 billion), about 1.2 times the size.
UroGen Pharma converts more of its revenue into profit, with a net margin of -139.8% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | URGN | VRDN |
|---|---|---|
| Share price | $36.83 | $18.66 |
| Market cap | $1.80B | $2.11B |
| 1-day change | -0.41% | +1.74% |
| YTD return | +57.26% | -40.04% |
| 1-year return | +124.30% | -14.44% |
| 5-year return | +116.39% | +9.31% |
| Forward P/E | 13.18 | — |
| EPS (TTM) | $-1.97 | $-3.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $109.79M | $70.85M |
| Revenue growth (YoY) | +21.45% | +23359.93% |
| Net income (latest FY) | $-153.49M | $-342.60M |
| Gross margin | 88.66% | — |
| Operating margin | -113.73% | -512.91% |
| Net margin | -139.81% | -483.57% |
| 52-week high | $50.81 | $34.29 |
| 52-week low | $16.18 | $13.18 |
| Distance from 52-week high | -27.51% | -45.58% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +62.91% | +96.95% |
| Average volume | 889.86K | 1.71M |
| Shares outstanding | 48.88M | 113.29M |
| Employees | 300 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed VRDN by 138.7 percentage points over the past year.
- UroGen Pharma is more profitable, keeping -139.8 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +21.45%).
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
URGN vs VRDN FAQ
Which is bigger, UroGen Pharma or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $2.11B compared with $1.80B for UroGen Pharma (URGN).
Which stock has performed better over the past year, URGN or VRDN?
URGN returned +124.30% over the past 12 months, compared with -14.44% for VRDN (price return, excluding dividends). Past performance does not predict future results.
Are UroGen Pharma and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.